BLFS - biolifesolutions.com Profit before deduction of interest, taxes, depreciation and amortization
The "razor and blade" model featuring high-margin consumables for cryochambers drives the dynamics of the base EBITDA, where 6.36 captures the value of this parameter. Management's strategy to create an indispensable biomaterial logistics infrastructure strengthens the position of BioLife Solutions, Inc. (BLFS). Current profit growth is based on demand in gene therapy and the gradual implementation of automated hubs.
Summary analytical data breakdowns for BioLife Solutions (BLFS)
- stock value and consensus price forecast:
- market capitalization statistics:
- book capitalization indicators:
- business debt structure and liquidity details:
Total Debt to Capital Coefficient BioLife Solutions, Inc.|BLFS - Long-Term Debt to Equity|Current Liabilities to Capital BioLife Solutions Inc|BLFS - Company Debts|Debt to Book Capitalization Ratio BioLife Solutions|BLFS - Company Long-Term Liabilities|Company Short-Term Debts BioLife Solutions|Intermediate Liquidity Ratio biolifesolutions.com
- earnings and market multiples details:
BLFS - Net Profit|Company Profit Forecast BioLife Solutions, Inc.|BLFS - Price to Earnings Ratio|Projected Price to Earnings Ratio biolifesolutions.com|BLFS - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation BioLife Solutions|BLFS - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters BioLife Solutions|BLFS - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months biolifesolutions.com|BLFS - Earnings growth in current year|Consensus forecast of earnings per share growth for next year BioLife Solutions, Inc.
Analysis of all company metrics:BioLife (BLFS)
Professional asset selection is based on an analysis of the stability of cash flows from core operations. This metric aggregates operating profit before depreciation and amortization, excluding the impact of tax and credit policies. EBITDA dynamics reflect the business's actual ability to generate liquidity. For BioLife Solutions, Inc. (BLFS), this confirms the effectiveness of scaling within the cryopreservation segment. The upward trend of the curve proves the company's indispensability in regenerative medicine supply chains.
Competitor analysis for BioLife Solutions, Inc.
Operating income before deduction of amortization Tempus (TEM)|Qiagen N.V. - Operating profit EBITDA|Profit before deduction of interest, taxes, depreciation and amortization IONS|RGEN: Operating profit EBITDA|Profit before interest, taxes and amortization Avidity Biosciences Inc (RNA)|Operating profit before deduction of amortization CRSP|WGS: Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Ultragenyx Pharmaceutical (RARE)|Operating income before deduction of amortization beamtx.com|Profit before payment of interest, taxes and amortization Sarepta SRPT|Twist Bioscience Inc (TWST) - Profit before interest, taxes and amortization|TXG - Profit before payment of interest, taxes and amortization|NTLA: Profit before payment of interest, taxes and amortization|STOK (Stoke Therapeutics) - Operating profit before deduction of amortization|wavelifesciences.com (WVE) - Operating profit EBITDA|Operating profit before deduction of amortization MAZE|SION (Sionna Therapeutics, Inc.) - Company profit before taxes, interest and amortization|Operating profit EBITDA PRME|Operating income before deduction of amortization Taysha Corp|Profit before payment of interest, taxes and amortization uniQure N.V. QURE|meiragtx.com (MGTX) - Profit before interest, taxes and amortization|RGNX - Profit before payment of interest, taxes and amortization|SLDB (Solid Biosciences Inc) - Operating profit before amortization|Ocugen Corp (OCGN) - Profit before payment of interest, taxes and amortization|PACB - Operating income before deduction of amortization|Operating profit before deduction of amortization BNTC|DSGN: Income before deduction of interest, taxes and amortization|Operating profit EBITDA RCKT|Operating income before deduction of amortization 4DMT|Profit before payment of interest, taxes and amortization Lexeo Therapeutics, Inc. LXEO|KRRO: Operating profit before amortization|Editas Medicine, Inc. - Operating profit EBITDA|silence-therapeutics.com (SLN) - Operating profit before deduction of amortization|PRQR (proqr.com) - Operating profit before deduction of amortization|CDXS - Operating income before deduction of amortization|SGMO (Sangamo) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization NAUT|Profit before payment of interest, taxes and amortization Metagenomi, Inc. (MGX)|Profit before payment of interest, taxes and amortization DTIL (precisionbiosciences.com)|Operating profit EBITDA GBIO (Generation Bio)|BOLD (Boundless Bio Inc.) - Profit before deduction of interest, taxes, depreciation and amortization|XCUR - Profit before payment of interest, taxes and amortization|Operating income before deduction of amortization Imunon, Inc. IMNN|PHIO: Operating profit EBITDA|Operating profit before amortization MBIO|Profit before payment of interest, taxes and amortization TransCode Therapeutics Inc.|Operating profit before amortization BNGO (Bionano)|Operating profit EBITDA APDN|Operating profit EBITDA bluebird bio, Inc (BLUE)|Operating profit EBITDA IPA (ImmunoPrecise Antibodies Ltd.)|omegatherapeutics.com - Profit before payment of interest, taxes and amortization|Singular Genomics - Operating profit EBITDA|Operating income before deduction of amortization Regulus Therapeutics, Inc. RGLS|Syros (SYRS) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Telesis Bio, Inc (TBIO)|Profit before payment of interest, taxes and amortization TRACON Pharmaceuticals|Profit before payment of interest, taxes and amortization UBX
